Gerasimos Aravantinos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3403957/publications.pdf

Version: 2024-02-01

90 papers	4,140 citations	185998 28 h-index	128067 60 g-index
93 all docs	93 docs citations	93 times ranked	7385 citing authors

#	Article	IF	Citations
1	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
2	The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection. Journal of Infection in Developing Countries, 2022, 16, 101-111.	0.5	4
3	Androgen Receptor andPIM1Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. Cancer Genomics and Proteomics, 2021, 18, 147-156.	1.0	4
4	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer: Targets and Therapy, 2021, Volume 12, 93-102.	1.3	1
5	Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Cancers, 2021, 13, 198.	1.7	10
6	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). Current Oncology, 2021, 28, 5266-5277.	0.9	1
7	Immune-related dermatologic toxicities: to make a long story short. Cutaneous and Ocular Toxicology, 2020, 39, 10-12.	0.5	1
8	Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?. Journal of Oncology Pharmacy Practice, 2020, 26, 747-753.	0.5	10
9	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. JAMA Network Open, 2020, 3, e1918939.	2.8	40
10	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	1.0	2
11	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 2020, 11, 1-14.	0.8	1
12	MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. International Journal of Colorectal Disease, 2019, 34, 1871-1877.	1.0	7
13	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 1915-1928.	6.3	1,804
14	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. ESMO Open, 2019, 4, e000441.	2.0	3
15	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2019, 20, 862-876.	5.1	68
16	Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. Cancer Biomarkers, 2019, 25, 213-221.	0.8	12
17	Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. Translational Oncology, 2019, 12, 739-748.	1.7	5
18	Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS ONE, 2019, 14, e0226853.	1.1	39

#	Article	IF	Citations
19	Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greeceâ€"â€"the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 491-501.	0.7	1
20	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International Journal of Clinical Oncology, 2019, 24, 411-419.	1.0	4
21	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Clinical Breast Cancer, 2018, 18, 53-62.e3.	1.1	8
22	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRIÂ+ Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e631-e637.	1.0	12
23	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. Oncotarget, 2018, 9, 35623-35638.	0.8	15
24	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Journal of Translational Medicine, 2017, 15, 30.	1.8	14
25	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 2017, 82, 237-246.	1.3	38
26	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
27	Anti-PD1/PDL1 induced psoriasis. Current Problems in Cancer, 2017, 41, 407-412.	1.0	90
28	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational Oncology, 2017, 10, 589-598.	1.7	17
29	Protein expression patterns of cell cycle regulators in operable breast cancer. PLoS ONE, 2017, 12, e0180489.	1.1	14
30	Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population. Anticancer Research, 2017, 37, 1105-1112.	0.5	18
31	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. Anticancer Research, 2017, 37, 2334.	0.5	10
32	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. Anticancer Research, 2017, 37, 2947-2957.	0.5	9
33	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. Cancer Genomics and Proteomics, 2017, 14, 181-195.	1.0	30
34	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. PLoS ONE, 2016, 11, e0163138.	1.1	8
35	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment, 2016, 158, 307-321.	1.1	16
36	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. Journal of Translational Medicine, 2016, 14, 136.	1.8	25

#	Article	IF	Citations
37	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clinical Breast Cancer, 2016, 16, 291-298.e3.	1.1	17
38	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS ONE, 2016, 11, e0164013.	1.1	4
39	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget, 2016, 7, 5074-5087.	0.8	54
40	Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer. Journal of Cancer Research and Therapeutics, 2016, 12, 193.	0.3	4
41	Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. Oncology Letters, 2015, 10, 2176-2184.	0.8	26
42	OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer. Forum of Clinical Oncology, 2015, 6, 1-7.	0.1	0
43	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. Journal of Translational Medicine, 2015, 13, 171.	1.8	15
44	Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial. PLoS ONE, 2015, 10, e0124612.	1.1	20
45	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS ONE, 2015, 10, e0140293.	1.1	29
46	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 75, 791-803.	1.1	46
47	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. Cancer Chemotherapy and Pharmacology, 2015, 75, 1289-1301.	1.1	6
48	Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study. Journal of Gastrointestinal Cancer, 2015, 46, 343-349.	0.6	9
49	Mutational Analysis of Circulating Tumor Cells from Colorectal Cancer Patients and Correlation with Primary Tumor Tissue. PLoS ONE, 2015, 10, e0123902.	1.1	45
50	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. Histology and Histopathology, 2015, 30, 1129-41.	0.5	2
51	Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. PLoS ONE, 2014, 9, e103707.	1.1	3
52	KRAS,NRASandBRAFmutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open, 2014, 4, e004652.	0.8	29
53	Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. Journal of Ovarian Research, 2014, 7, 57.	1.3	52
54	Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer, 2013, 13, 263.	1.1	68

#	Article	IF	Citations
55	Aims, design and methods of a caseâ€"control study for the assessment of the role of dietary habits, eating behaviors and environmental factors, on the development of breast cancer. Maturitas, 2013, 74, 31-36.	1.0	12
56	Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. PLoS ONE, 2013, 8, e58182.	1.1	27
57	Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk. Molecular Medicine Reports, 2013, 7, 887-892.	1.1	14
58	E-Selectin S128R Gene Polymorphism in Gastric Cancer. International Journal of Biological Markers, 2013, 28, 38-42.	0.7	4
59	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Journal of Translational Medicine, 2012, 10, 10.	1.8	46
60	Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression. Clinical Breast Cancer, 2012, 12, 183-193.	1.1	49
61	Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: A Hellenic Cooperative Oncology Group (HeCOG) study. Oncology Reports, 2011, 27, 216-24.	1.2	12
62	Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells. Journal of Cancer Research and Clinical Oncology, 2011, 137, 359-374.	1.2	10
63	Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Gastric Cancer, 2011, 14, 317-321.	2.7	34
64	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. BMC Medicine, 2011, 9, 10.	2.3	41
65	A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine, 2010, 8, 3.	2.3	42
66	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology, 2009, 2009, 1-17.	0.6	29
67	Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group. Oncology, 2009, 77, 107-112.	0.9	26
68	Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. International Journal of Oncology, 2009, 34, 137-60.	1.4	15
69	Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. International Journal of Oncology, 2009, 35, 401-16.	1.4	29
70	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Critical Reviews in Oncology/Hematology, 2008, 66, 237-247.	2.0	37
71	Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. Gynecologic Oncology, 2008, 108, 47-52.	0.6	7
72	Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. European Journal of Cancer, 2008, 44, 2169-2177.	1.3	19

#	Article	IF	Citations
73	Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study. Cancer Investigation, 2008, 26, 491-498.	0.6	6
74	Gemcitabine versus Gemcitabineâ€"Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Thoracic Oncology, 2007, 2, 135-140.	0.5	44
75	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. Oncology, 2007, 72, 388-396.	0.9	16
76	Comparison of HER2 Detection Methods Between Central and Regional Laboratories in Greece. Clinical Breast Cancer, 2007, 7, 784-790.	1.1	7
77	Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer. Medical Oncology, 2007, 24, 301-307.	1.2	3
78	Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma. Oncology, 2006, 70, 280-284.	0.9	25
79	Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecologic Oncology, 2005, 97, 436-441.	0.6	133
80	Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study. Cancer Investigation, 2005, 23, 9-12.	0.6	45
81	The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology, 2005, 66, 382-385.	0.5	6
82	Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Research, 2005, 25, 3103-8.	0.5	18
83	Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG). Tumori, 2005, 91, 309-13.	0.6	1
84	Oxaliplatin and Irinotecan plus Granulocyte-Colony Stimulating Factor as Third-Line Treatment in Relapsed or Cisplatin-Refractory Germ-Cell Tumor Patients:A Phase II Study. European Urology, 2004, 46, 216-221.	0.9	48
85	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Anti-Cancer Drugs, 2004, 15, 479-487.	0.7	5
86	A Phase III Study of 5-Fluorouracil Versus 5-Fluorouracil Plus Interferon Alpha 2b Versus 5-Fluorouracil Plus Leucovorin in Patients With Advanced Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 23-30.	0.6	9
87	Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study. Cancer Investigation, 2000, 18, 503-509.	0.6	57
88	Dose-Dense Adjuvant Chemotherapy with Epirubicin Monotherapy in Patients with Operable Breast Cancer and â‰¥10 Positive Axillary Lymph Nodes. Oncology, 1998, 55, 508-512.	0.9	17
89	Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology, 1997, 50, 754-758.	0.5	78
90	Megestrol Acetate in Cancer Patients with Anorexia and Weight Loss a Hellenic co-operative oncology group (HeCOG) study. Acta OncolÃ³gica, 1993, 32, 37-41.	0.8	8